Global Compliance, Made Simple.

EUDAMED Registration: Step-by-Step Guide for Medical Device Manufacturers

EUDAMED registration is the process by which medical device manufacturers submit their device-level data — Basic UDI-DI, UDI-DI, certificates, and related attributes — into the European Database on Medical Devices. Once mandatory, this registration becomes the regulatory anchor that connects every device placed on the EU market to its identification, traceability, and post-market obligations.

This guide focuses on what most manufacturers actually need to operationalize: the registration of devices and their identifiers. It covers Basic UDI-DI submission, UDI-DI linkage, certificate referencing, the practical sequence of steps, and the choice between manual entry and machine-to-machine (M2M) automation.

For broader context on the database itself, see our overview of EUDAMED and the six EUDAMED modules that structure the system.

Scope note. This article addresses device-level registration. Operational topics that fall outside ACKOMAS’ regulatory scope are not covered here.

GUDID at the Heart of the FDA Framework: In-Depth Analysis of Its Link to Compliance Program 7382.850

The FDA’s 7382.850 Compliance Program, which takes effect on February 2, 2026, is designed for inspections of medical device manufacturers and outlines how inspectors assess manufacturers’ compliance with the entire U.S. regulatory framework. While the document covers a broad scope (QMSR, MDR, tracking, corrections & removals, PMA, import/export…), it assigns a major role to the UDI System and the GUDID (Global Unique Device Identification Database), considered essential components of patient safety, traceability, and postmarket surveillance.

This connection, sometimes implicit in industry practices, is formally established here and integrated into the FDA’s inspection approach. This article explores that link in detail.

GUDID & EUDAMED: What Inspection Frameworks Reveal About Regulatory Data Governance

Regulatory authorities increasingly rely on structured, risk-based inspection models that evaluate more than documentation completeness. Inspections now examine data consistency, traceability, lifecycle continuity, and overall data integrity across regulatory systems.

In the United States, the FDA Compliance Program 7382.850 – Inspection of Medical Device Manufacturers provides a detailed description of how inspections are conducted. Although designed for the U.S. regulatory environment, its logic reveals a universal principle: inspection readiness depends on the maturity of regulatory data governance.

In Europe, MDR (EU 2017/745) and IVDR (EU 2017/746) establish EUDAMED as a multilayered data environment that reinforces transparency and interconnected regulatory oversight.

For global regulatory teams, this raises a critical question: What do GUDID and EUDAMED reveal about the requirements for disciplined regulatory data governance?